Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 11032 results:
[ Συντάκτης(Desc)] Τίτλος Τύπος Έτος
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
K
Karagiannis, A., Tziomalos K., & Athyros V. G. (2007).  Is angioedema a class adverse effect of the angiotensin-converting enzyme inhibitors?. Ann Allergy Asthma Immunol. 98(5), 502.
Karagiannis, A. D., Liu M., Toth P. P., Zhao S., Agrawal D. K., Libby P., et al. (2018).  Pleiotropic Anti-atherosclerotic Effects of PCSK9 InhibitorsFrom Molecular Biology to Clinical Translation.. Curr Atheroscler Rep. 20(4), 20.
Karagiannis, T., Liakos A., Branda M. E., Athanasiadou E., Mainou M., Boura P., et al. (2016).  Use of the Diabetes Medication Choice Decision Aid in patients with type 2 diabetes in Greece: a cluster randomised trial. BMJ Open. 6(11), e012185.
Karagiannis, A., Balaska K., Tziomalos K., Gerasimidis T., Karamanos D., Papayeoryiou A., et al. (2004).  Lack of an association between angiotensin converting enzyme gene polymorphism and peripheral arterial occlusive disease.. Vasc Med. 9(3), 189-92.
Karagiannis, T., Avgerinos I., Liakos A., Del Prato S., Matthews D. R., Tsapas A., et al. (2022).  Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.. Diabetologia. 65(8), 1251-1261.
Karagiannis, T., & Bekiari E. (2016).  Most add-on therapies to metformin have similar effects on HbA1c.. Evid Based Med. 21(6), 223.
Karagiannis, A. K. A., Dimitropoulou F., Papatheodorou A., Lyra S., Seretis A., & Vryonidou A. (2016).  Pituitary abscess: a case report and review of the literature.. Endocrinol Diabetes Metab Case Rep. 2016, 160014.
Karagiannis, A., Tziomalos K., Dona K., Pyrpasopoulou A., Kartali N., Athyros V., et al. (2005).  Bilateral renal artery stenosis and primary aldosteronism in a diabetic patient.. QJM. 98(12), 913-5.
Karagiannis, A., Athyros V. G., Papageorgiou A., Tziomalos K., & Elisaf M. (2006).  Should atenolol still be recommended as first-line therapy for primary hypertension?. Hellenic J Cardiol. 47(5), 298-307.
Karagiannis, A., Douma S., Voyiatzis K., Petidis K., Athyros V., Vizantiadis A., et al. (1995).  Percutaneous transluminal renal angioplasty in patients with renovascular hypertension: long-term results.. Hypertens Res. 18(1), 27-31.
Karagiannis, A., Tziomalos K., Anagnostis P., Gossios T. D., Florentin M., Athyros V. G., et al. (2010).  The effect of antihypertensive agents on insulin sensitivity, lipids and haemostasis.. Curr Vasc Pharmacol. 8(6), 792-803.
Karagiannis, A., Mikhailidis D. P., Tziomalos K., Kakafika A. I., & Athyros V. G. (2008).  Has the time come for a new definition of microalbuminuria?. Curr Vasc Pharmacol. 6(2), 81-3.
Karagiannis, T., Bekiari E., & Tsapas A. (2023).  Socioeconomic aspects of incretin-based therapy.. Diabetologia. 66(10), 1859-1868.
Karagiannis, T., Bekiari E., Manolopoulos K., Paletas K., & Tsapas A. (2011).  Gestational diabetes mellitus: why screen and how to diagnose.. Hippokratia. 15(2), 187-8.
Karagiannis, T., Tsapas A., & Bekiari E. (2021).  KDIGO made 12 recommendations for managing diabetes with CKD.. Ann Intern Med. 174(3), JC26.
Karagiannis, A., Mikhailidis D. P., Kakafika A. I., Tziomalos K., & Athyros V. G. (2007).  Atenolol: differences in mode of action compared with other antihypertensives. An opportunity to identify features that influence outcome?. Curr Pharm Des. 13(2), 229-39.
Karagiannis, A., Tziomalos K., Patsiaoura K., Nikolaidis N., Giouleme O., Mavroudis N., et al. (2004).  Focal nodular hyperplasia of the liver in a patient with primary aldosteronism.. J Gastroenterol Hepatol. 19(4), 480-1.
Karagiannis, A., Tziomalos K., Papageorgiou A., Kakafika A. I., Pagourelias E. D., Anagnostis P., et al. (2008).  Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.. Expert Opin Pharmacother. 9(4), 509-15.
Karagiannis, A., Athyros V. G., & Mikhailidis D. P. (2009).  A comparison of the aldosterone-blocking agents eplerenone and spironolactone.. Clin Cardiol. 32(4), 230.
Karagiannis, A., Tziomalos K., Krikis N., Sfikas G., Dona K., & Zamboulis C. (2005).  The unilateral measurement of blood pressure may mask the diagnosis or delay the effective treatment of hypertension.. Angiology. 56(5), 565-9.
Karagiannis, A., Douma S., Vogiatzis K., Petidis K., Doumas M., Vyzantiadis A., et al. (1994).  The relationship between the sympathetic nervous system and the renin-angiotensin system in renovascular hypertension.. Acta Cardiol. 49(5), 425-34.
Karagiannis, A., Hatzitolios A. I., Athyros V. G., Deligianni K., Charalambous C., Papathanakis C., et al. (2009).  Implementation of guidelines for the management of arterial hypertension. The impulsion study.. Open Cardiovasc Med J. 3, 26-34.
Karagiannis, A. K., Philippou A., Tseleni-Balafouta S., Zevolis E., Nakouti T., Tsopanomichalou-Gklotsou M., et al. (2019).  IGF-IEc Expression Is Associated With Advanced Differentiated Thyroid Cancer.. Anticancer Res. 39(6), 2811-2819.
Karagiannis, A., Tsorlalis I., Kakafika A., Pateinakis P., Perifanis V., & Harsoulis F. (2005).  Acute renal failure due to tumor lysis syndrome in a patient with non-Hodgkin's lymphoma.. Ann Hematol. 84(5), 343-6.
Karagiannis, T., Liakos A., Branda M. E., Athanasiadou E., Mainou M., Boura P., et al. (2016).  Use of the Diabetes Medication Choice Decision Aid in patients with type 2 diabetes in Greece: a cluster randomised trial.. BMJ Open. 6(11), e012185.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές